Document Type

Article

Publication Date

4-16-2024

Comments

This article is the author’s final published version in Medical Cannabis and Cannabinoids, Volume 7, Issue 1, 2024, Pages 80-85.

The published version is available at https://doi.org/10.1159/000538694. Copyright © 2024 The Author(s). Published by S. Karger AG, Basel.

Publication made possible in part by support from the Jefferson Open Access Fund

Abstract

INTRODUCTION: Subjective improvement in gastrointestinal (GI) symptoms was assessed among patients using medical marijuana (MMJ).

METHODS: Participants completed surveys at 0 days, 30 days, 6 months, and 12 months with questions about the severity of their GI symptoms on a scale from 1 (mild) to 3 (severe).

RESULTS: In each survey, participants reported a significant decrease in GI symptom severity when using MMJ versus when not using MMJ (p < 0.05). The most common self-reported side effects from using MMJ were increased appetite (12-21.4%), fatigue (6-16.7%), anxiety (4-11.9%), cough (4-11.9%), headache (6-7.9%), and dry mouth (4-7.1%).

CONCLUSION: In patients with chronic GI symptoms, MMJ may provide persistent symptom severity improvement. Limited product availability and mild to moderate side effects are factors to consider before trialing MMJ.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

PubMed ID

39015606

Language

English

Share

COinS